CTOs on the Move


 
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vical.com
  • 10390 Pacific Center Ct
    San Diego, CA USA 92121
  • Phone: 858.646.1100

Executives

Name Title Contact Details

Similar Companies

PharmaMed Resources

PharmaMed Resources is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innoviant Pharmacy

Innoviant Pharmacy is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Suvoda

Suvoda’s sole focus is to offer the industry’s leading SaaS solution for randomization and trial supply management. Suvoda’s Interactive Response Technology (IRT/IWRS) combines the flexibility of a custom solution with the speed of a configurable platform, offering 4-week deployment, reimagined reporting, and easy integration.

Embecta

Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.